Issue Date: November 7, 2011
Biotie And Newron Drop Takeover Plan
Finland’s Biotie Therapeutics has decided not to acquire Newron Pharmaceuticals following Merck KGaA’srecent decision to return to Newron the rights to safinamide, a compound being developed as a Parkinson’s disease treatment. Newron, based in Milan, says it is considering all strategic options for the drug, which is currently in late Phase III clinical trials.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society